Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early ...

Appointments strengthen Picard’s Board with proven expertise in capital markets and global MedTech leadershipTUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the appointment of two new members that will serve on its Board of Directors, Sam Van and George Ye. Both were appointed following the ...

TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at $4.00 per share (the “Offering”). The Company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of Common Stock the public offering price, less underwri ...

公司IPO及融资详情 - 公司完成首次公开发行 发行425万股普通股 每股定价4美元 总融资额1700万美元（未扣除承销折扣和发行费用）[1] - 承销商享有30天超额配售选择权 可额外购买637,500股普通股[1] - 股票预计于2025年8月29日在NYSE American交易所上市交易 股票代码为"PMI"[1] 承销团队及法律顾问 - WestPark Capital担任主承销商和独家簿记管理人 Sentinel Brokers担任联合管理人[2] - E.F. Hutton和Uphorizon担任发行人财务顾问[2] - Winston & Strawn律师事务所担任公司法律顾问 Sheppard Mullin担任承销商法律顾问[2] 资金用途规划 - 融资资金将用于支持中国市场扩张 通过合资企业SynCardia Medical (Beijing)进行运营[3] - 部分资金将投入产品研发 包括全植入式无人驱动版本"Emperor"及新一代便携式驱动系统[3] - 资金还将用于增强销售营销能力 扩大库存和驱动器基数 偿还债务以及支付一般运营费用[3] 公司业务概况 - 公司是SynCardia Systems母公司 拥有唯一获FDA和加拿大卫生部批准的全人工心脏(STA)技术[6] - SynCardia Total Artificial Heart是全球应用最广泛的人工心脏 已在27个国家完成2100例植入[6] - 该技术是目前美国和加拿大唯一商业化可用的人工心脏产品[6] 监管备案信息 - 公司已向SEC提交S-1注册声明（文件编号333-286295）并于2025年8月12日宣布生效[4] - 最终招股说明书可通过WestPark Capital或SEC官方网站获取[4]